|
|
|
|
|
19.12.25 - 09:42
|
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® (GlobeNewswire EN)
|
|
|
REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept) in the United States. The settlement grants a license entry date for AVT06 in the United States in the fourth quarter of 2026, or earlier under certain circumstances....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.12.25 - 14:06
|
TRIANA Biomedicines Announces Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline (Business Wire)
|
|
|
Financing co-led by new investors, Ascenta Capital and Bessemer Venture Partners
Additional new investors included YK Bioventures, Regeneron Ventures, Invus, and Finchley Healthcare Ventures, along with continued support from existing investors
Funding will support the advancement of lead asset, TRI-611, an ALK-targeted molecular glue degrader, to clinical proof of concept, for ALK+ NSCLC patients and accelerate maturation of multiple pipeline programs
LEXINGTON, Mass.--(BUSINESS WIRE)--TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced the successful closing of its oversubscribed $120 million Series B financing round.
The Series B financing was co-led by Ascenta Capital and Bessemer Venture Partners. New investors included YK Bioventures, Regeneron Ventures, Invus, and Finchley Healthcare Ventures. TRIANA received continued support fr...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.11.25 - 11:48
|
AKTIONÄR-Tipp Regeneron gibt kräftig Gas – jetzt noch zugreifen? (Der Aktionaer)
|
|
|
Erst Anfang November hat DER AKTIONÄR die Aktie des US-Biotech-Unternehmens Regeneron zum Kauf empfohlen. Mittlerweile konnte das Papier wieder ordentlich Fahrt aufnehmen und notiert bereits mehr als 23 Prozent im Plus. DER AKTIONÄR verrät, dass die Aktie zuletzt beflügelt hat, was in nächster Zeit zu erwarten ist und ob auch jetzt noch ein Einstieg lohnt....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
